Geode Capital Management LLC Has $73.22 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,472,899 shares of the specialty pharmaceutical company’s stock after purchasing an additional 62,875 shares during the period. Geode Capital Management LLC owned 2.57% of Supernus Pharmaceuticals worth $73,215,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Hantz Financial Services Inc. increased its stake in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $49,000. Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Supernus Pharmaceuticals by 532.4% during the 4th quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 1,182 shares during the last quarter. Finally, Vestcor Inc acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $67,000.

Supernus Pharmaceuticals Stock Down 0.6%

NASDAQ SUPN opened at $44.48 on Tuesday. The company has a market capitalization of $2.58 billion, a P/E ratio of -87.22, a P/E/G ratio of 0.96 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a 12-month low of $30.83 and a 12-month high of $59.68. The firm has a 50-day moving average price of $49.11 and a two-hundred day moving average price of $49.56.

Analyst Ratings Changes

Several research firms have recently weighed in on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares of the company’s stock, valued at $48,259,497. The trade was a 3.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 7,250 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at $845,382.40. This represents a 29.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 97,619 shares of company stock valued at $4,908,275 in the last quarter. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.